Acquired aplastic anemia

Annals of Internal Medicine

Volumn 136, Issue 7, 2002, Pages 534-546

  Young, Neal S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; BONE MARROW DEPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0037006957     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-7-200204020-00011     Document Type: Review

References (62)

1. Ueber einem fall von anämie mit bemerkungen über regenerative veränderungen des knochenmarks
2. Drugs and chemicals
3. The pathophysiology of acquired aplastic anemia
4. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia
5. Progressive telomere shortening in aplastic anemia
6. Transfusion-associated graft-versus-host disease
7. Bone marrow and peripheral blood lymphocytes of patients with severe aplastic anemia contain ifn-γ detectable by flow cytometric analysis
8. A mouse model of immune-mediated aplastic anemia
9. Limited heterogeneity of T cell receptor BV usage in aplastic anemia
10. Congenital bone marrow failure syndromes
11. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?
12. Immune modulation of myelodysplasia: Rationale and therapy
13. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes
14. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome
15. Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria
16. Superior growth of glycosylphosphatidylinositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo
17. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: This little PIG-A goes "Why? Why? Why?"
18. Hepatitis-associated aplastic anemia
19. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation
20. Parvovirus B19 in human disease
21. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children
22. Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis
23. Acute sporadic non-A, non-B, non-C, non-D, non-D, non-E hepatitis
24. Acute viral hepatitis in Hanoi, Viet Nam
25. Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection
26. Regional patterns in the incidence of aplastic anemia in Thailand
27. Incidence survey of aplastic anemia in China
28. The treatment of severe acquired aplastic anemia
29. Allogenic bone marrow transplantation for leukemias and aplastic anemia
30. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia
31. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience
32. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia
33. Long-term outcome after marrow transplantation for severe aplastic anemia
34. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults
35. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia
36. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
37. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation
38. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia
39. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia
40. Solid cancers after bone marrow transplantation
41. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine
42. Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party
43. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia
44. A randomized trial of standard immunosuppression versus cyclosporine and filgrastim in severe aplastic anemia
45. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation
46. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
47. High-dose cyclophosphamide in severe aplastic anaemia: A randomised trial
48. A randomized trial comparing antithymocyte globulin and cyclosporin to cyclophosphamide and cyclosporin for initial treatment in severe aplastic anemia: Results of long-term follow-up
49. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins
50. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin
51. Long-term outcome in severe aplastic anemia is predicted by blood counts after treatment with intensive immunosuppression
52. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy
53. Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone
54. Haemopoietic growth factors in aplastic anaemia: A cautionary note
55. Results of a randomized study of glycosylated rHuGCSF lenograstim in severe aplastic anemia
56. Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony-stimulating factor in children with aplastic anemia and very severe neutropenia
57. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: A multicenter randomized controlled study
58. Use of stem cell factor (Sremgen®, SCF) and filgastrim (G-CSF) in aplasric anemia (AA) patients (Prs) who have failed ATG/ALG therapy
59. Malignant tumors occurring after treatment of aplastic anemia
60. Long-term (5 to 20 years) Evolution of nongrafted aplastic anemias
61. Treatment of bone marrow failure of myelodysplastic syndrome with anrithymocyte globulin